Table 2.
Laboratory values and treatment data at treatment initiation among new users, by country and type of treatment started.
| Brazil | Germany | US | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Oral Iron | IV Iron | ESA | Oral Iron | IV Iron | ESA | Oral Iron | IV Iron | ESA | |
| Patients, N | 53 | 18 | 32 | 181 | 93 | 178 | 136 | 27 | 48 |
| % on monotherapy | 94% | 44% | 59% | 92% | 73% | 83% | 95% | 81% | 83% |
| Laboratory values* | |||||||||
| CKD stage | |||||||||
| Stage 3 | 23% | 11% | 19% | 22% | 13% | 6% | 30% | 14% | 13% |
| Stage 4 | 66% | 39% | 42% | 62% | 61% | 54% | 52% | 64% | 41% |
| Stage 5 | 11% | 50% | 39% | 16% | 26% | 39% | 18% | 23% | 46% |
| eGFR, ml/min/1.73m2 | 25.0 (9.9) | 18.2 (11.8) | 19.8 (10.3) | 24.2 (10.2) | 21.2 (9.2) | 18.1 (7.5) | 25.3 (11.5) | 19.8 (8.1) | 18.8 (9.2) |
| Hemoglobin, g/dL | 11.5 (1.3) | 10.4 (1.6) | 10.9 (1.6) | 11.2 (1.5) | 11.2 (1.4) | 10.2 (1.3) | 11.1 (1.6) | 10.2 (1.7) | 9.6 (1.4) |
| Ferritin, ng/mL |
99 [50,281] |
100 [90,162] |
143 [98,346] |
89 [46,171] |
110 [51,191] |
180 [90,362] |
87 [50,247] |
61 [30,225] |
200 [133,370] |
| Ferritin < 100 ng/mL | 52% | 43% | 25% | 58% | 48% | 28% | 55% | 58% | 17% |
| TSAT, % | 28.5 (11.5) | 19.3 (9.7) | 28.3 (10.5) | 17.8 (9.0) | 20.0 (11.1) | 21.8 (8.7) | 18.4 (9.1) | 15.6 (7.0) | 29.4 (10.1) |
| TSAT < 20% | 18% | 60% | 17% | 69% | 61% | 43% | 60% | 82% | 13% |
| ESA type | |||||||||
| Patients with ESA type data, N | 2 | 10 | 29 | 10 | 21 | 178 | 5 | 3 | 40 |
| Darbepoetin alfa | 0% | 0% | 3% | 30% | 62% | 54% | 40% | 0% | 65% |
| Epoetin alfa | 100% | 100% | 97% | 60% | 24% | 25% | 60% | 67% | 33% |
| Epoetin beta – pegylated | 0% | 0% | 0% | 10% | 19% | 22% | 0% | 33% | 3% |
Patients who are under combined treatment regimen could contribute to any of three columns.
*The most recent value within 12 months prior to the treatment initiation.
Results presented as Number, mean (SD), median [IQR] or percentage as appropriate.